JNJoshua Chukwufumnanya Nwabuife

Joshua Chukwufumnanya Nwabuife

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joshua Chukwufumnanya Nwabuife has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liposomal Delivery Systems for Improved Delivery of Docetaxel Against Prostate Cancer

    by Joshua Nwabuife, Mamello Sekhoacha

    Generally, liposomes as a delivery system have been vastly designed for the delivery of therapeutic agents, to overcome various drawbacks, including resistance imposed to various conventional forms of these agents. They are significantly advantageous compared to other kinds of delivery systems because of their ability to deliver hydrophobic and hydrophilic therapeutic agents singly as monotherapy or combined as combinational therapy, owing to bilayer formation. Clinically, liposomes have been applied for delivery of therapeutic agents, with the aim of improving target-site-specificity and reducing toxicity to normal cells or tissues caused by chemotherapeutic drugs, which makes them relatively better options compared to the conventional forms of delivery system. Herein, a critical review which extensively discusses the various liposomal systems of delivery used for docetaxel (DTX) delivery against prostate cancer in the past decade, either alone as mono-therapeutical delivery or in combination with other therapeutic agents is presented. This review affirms to the potentials of employing liposomal systems of delivery for the effective targeted delivery of DTX against prostate cancer.


  • Open Access

    Engineering nanoplex platforms for enhanced transfection and gene expression in cancer therapy

    by Daniel Hassan, Joshua C. Nwabuife, Emmanuel C. Eze, Vincent O. Nyandoro, Vijayakumar Murugesan, Mamello P. Sekhoacha, Thirumala Govender, Calvin A. Omolo

    Cancer remains a leading cause of morbidity and mortality worldwide, accounting for millions of new cases and deaths annually. Despite advances in conventional chemotherapy, treatment outcomes are often limited by poor selectivity, systemic toxicity, drug resistance and suboptimal pharmacokinetics. Nucleic acid-based therapies are promising strategies for targeted cancer treatment; however, their clinical application is hindered by rapid degradation, poor cellular uptake and low transfection efficiency. Nanotechnology-based delivery systems have therefore been explored to overcome these barriers. Among these, nanoplexes are a versatile platform for gene delivery due to their ability to complex, protect and transport nucleic acids into target cells. This review focuses on the engineering of nanoplex platforms for enhanced transfection and gene expression in cancer therapy. We provide a comprehensive analysis of the current progress in nanoplex design and application and discuss advances in nanoplex-mediated gene delivery across cancer types, highlighting their transfection efficiency, gene expression, gene knockdown and safety profiles. Brief comparisons with other non-viral delivery systems are included to contextualize their relative advantages and limitations. Finally, the review outlines key challenges and future opportunities for the clinical translation of nanoplex-based gene therapies.

  • Open Access

    Novel folic acid-functionalized smart Eicosapentaenoic acid liposomes for the targeted delivery of quercetin against cancer

    by Amanda N. Ngcamu, Joshua C. Nwabuife, Nokukhanya P. Ndimande, Samkelsiwe Gabela, Terisha Ghazi, Mamello P. Sekhoacha, Mbuso A. Faya


  • Novel vancomycin free base – Sterosomes for combating diseases caused by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus infections (S. Aureus and MRSA)

    by Joshua C. Nwabuife, Daniel Hassan, Amit Madhaorao Pant, Nikita Devnarain, Mohammed Ali Gafar, Nawras Osman, Sanjeev Rambharose, Thirumala Govender


  • Open Access

    Novel Vancomycin Free Base – Sterosomes for Combating Diseases Caused by Staphylococcus Aureus Infections (S. Aureus and MRSA)

    by Joshua Chukwufumnanya Nwabuife, Daniel Hassan, Amit Madhaorao Pant, Nikita Devnarain, Mohammed Ali Gafar, Nawras Osman, Sanjeev Rambharose, Chunderika Mocktar, Thirumala Govender

    A clarion call to save antibiotics and other antimicrobials is the need for the evolution of novel drug delivery systems to combat resistance posed by Staphylococcus aureus and Methicillin- resistant Staphylococcus aureus (S. aureus and MRSA) to the conventional drug delivery systems. Herein, we present a novel vancomycin free base – sterosomes (VCM-FB – Sterosomes) for vancomycin free base (VCM-FB) delivery against S. aureus and MRSA. VCM-FB – Sterosomes were prepared by employing the thin-film hydration method and assessed in terms of their physicochemical, in silico, in vitro and in vivo properties. A preliminary biocompatibility evaluation on MCF-7 and HEK-293 cell lines was also carried out on the VCM-FB – Sterosomes formulation using in vitro cytotoxicity assay. The cytotoxicity results revealed the viability of cell to be above 70% for all the cell lines after exposure to VCM-FB – Sterosomes, therefore indicating its biosafety. VCM-FB – Sterosomes had hydrodynamic diameter (DH), polydispersity index (PDI) and a surface-charge (ζ) of 114.14 ± 0.59 nm, 0.210 ± 0.02 and +36.3 ± 5.42 mV respectively, with an entrapment efficiency (EE%), drug loading capacity (DLC%) and VCM-FB release after 48-hour of 79.61 ± 0.59%, 90.91% w/w and 54.95 ± 9.75% respectively. In silico studies showed VCM-FB – Sterosomes to self-assemble in five nano seconds and was stable thereafter. Stability studies also showed the VCM-FB – Sterosomes formulation to be stable over a period of 90 days while the in vitro haemolytic studies showed VCM-FB – Sterosomes to be non-hemolytic. Interestingly, the VCM-FB – Sterosomes showed 2-fold superior minimum inhibition efficiency (MIC) against S. aureus and MRSA relative to bare VCM-FB with MICs of 1.95 µg/mL and 0.98 µg/mL for VCM-FB and VCM-FB – Sterosomes (S. aureus), and 7.81 µg/mL and 3.91 µg/mL for VCM-FB and VCM-FB – Sterosomes (MRSA), respectively. Blank Sterosomes were also observed to be effective against these bacteria, with greater effectiveness observed against MRSA. Faster bacterial killing time was also recorded for VCM-FB – Sterosomes compared to bare VCM-FB.Greater damage to the MRSA membrane was indicated by an increase and decrease in electrical conductivity, and protein/DNA concentration, respectively. VCM-FB – Sterosomes were observed to exhibit a superior reduction of matured MRSA biofilm (27.22%) compared to VCM-FB (2.53%). In vivo BALB/c mice-infected skin model showed VCM-FB – Sterosomes to have a more significant MRSA eradication of 27-fold compared to bare VCM-FB, which showed an approximately 4-fold MRSA eradication. The result of this study amplifies the superior efficiency of VCM-FB – Sterosomes for the treatment of S. aureus and MRSA infections compared to conventional form of VCM-FB.